Exact Sciences Corp
NASDAQ:EXAS
Exact Sciences Corp
NASDAQ:EXAS
Price:
63.2 USD
4.39%
Updated:
May 3, 2024
Exact Sciences Corp
Cash from Financing Activities
|
Exact Sciences Corp
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Cash from Financing Activities
$159.8m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Exact Sciences Corp's Cash from Financing Activities?
Cash from Financing Activities
159.8m
USD
159.8m
USD
Based on the financial report for Dec 31, 2023, Exact Sciences Corp's Cash from Financing Activities amounts to 159.8m USD.
What is Exact Sciences Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
8%
8%
Over the last year, the Cash from Financing Activities growth was 109%. The average annual Cash from Financing Activities growth rates for Exact Sciences Corp have been -56% over the past three years , -30% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
